Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) had its price objective hoisted by research analysts at HC Wainwright from $11.00 to $12.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.
Several other research analysts have also commented on BDTX. Wedbush restated an “outperform” rating and set a $11.00 price target (down previously from $16.00) on shares of Black Diamond Therapeutics in a research note on Friday, March 7th. Stifel Nicolaus lowered their target price on shares of Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $14.60.
Check Out Our Latest Stock Report on BDTX
Black Diamond Therapeutics Price Performance
Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03. On average, equities analysts anticipate that Black Diamond Therapeutics will post -1.3 EPS for the current year.
Institutional Trading of Black Diamond Therapeutics
Several large investors have recently modified their holdings of BDTX. D. E. Shaw & Co. Inc. bought a new position in Black Diamond Therapeutics in the 4th quarter worth $37,000. Intech Investment Management LLC grew its position in shares of Black Diamond Therapeutics by 49.1% in the fourth quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock valued at $41,000 after purchasing an additional 6,340 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Black Diamond Therapeutics by 429.6% in the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after purchasing an additional 15,355 shares during the period. SG Americas Securities LLC acquired a new position in shares of Black Diamond Therapeutics during the 4th quarter worth about $42,000. Finally, Wells Fargo & Company MN lifted its position in shares of Black Diamond Therapeutics by 41.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock worth $43,000 after purchasing an additional 5,932 shares during the last quarter. 95.47% of the stock is owned by institutional investors.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.
Read More
- Five stocks we like better than Black Diamond Therapeutics
- ESG Stocks, What Investors Should Know
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
- Are Penny Stocks a Good Fit for Your Portfolio?
- Southwest Airlines Could Triple From Here—Here’s How
- There Are Different Types of Stock To Invest In
- Salesforce: An Early AI Opportunity With Long-Term Potential
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.